Head and neck cancer (HNC) continues to be a major cause of death and disfigurement, and therapies for HNC have not improved significantly in the last several decades. There is now convincing evidence that a subset of HNC, particularly those from the oropharyngeal (tonsillar) region, are caused by human papillomavirus (HPV). Over 50% of oropharyngeal cancers contain and express the E6/E7 genes from HPV, mostly HPV-16, a subtype that is frequently involved in the development of cervical cancer. Our studies have demonstrated that HPV-16 E6/E7 can immortalize and transform human and mouse tonsillar epithelial cells. While it has been demonstrated that inhibition of HPV genes in cancer cell lines can effectively suppress transformation in vitro, current strategies of inhibition are relatively non-specific and inefficient for in vivo delivery. We have developed a unique mouse model of HNC in which HPV-16 E6/E7 mouse tonsillar epithelial cells (MTECs) are transformed to tumorigenicity by expression of mutant Ras or ErbB2. This unique HNC model systemwill allow the assessment of methods to inhibit HPV genes to suppress tumorigenic growth in a syngeneic immunocompetent host. Our group has previously shown that chimeric all RNA aptamer-siRNAs can be utilized in vivo for specific binding, internalization, and delivery of siRNAs into target cells. Here, we propose to develop RNA aptamers that specifically localize and internalize into HPV transformed MTECs. Aptamer-siRNA chimeras that target HPV genes will then be tested for their ability to specifically inhibit growth of HPV transformed tonsillar epithelial cells in vitro and in vivo. Overall, our proposed proof-of-concept studies could lead to the development of more specific and effective methods to treat HPV associated oropharyngeal cancer and other oral diseases.
The development of novel methodologies to specifically and efficiently inhibit HPV genes in transformed tonsillar epithelial cells could lead to advanced treatment methods for head and neck cancer. The findings from this work could be applicable to the treatment of other oral diseases, as well.
|Kruspe, Sven; Giangrande, Paloma H (2017) Design and Preparation of Aptamer-siRNA Chimeras (AsiCs) for Targeted Cancer Therapy. Methods Mol Biol 1632:175-186|
|Dickey, David D; Thomas, Gregory S; Dassie, Justin P et al. (2016) Method for Confirming Cytoplasmic Delivery of RNA Aptamers. Methods Mol Biol 1364:209-17|
|Urak, Kevin T; Shore, Sabrina; Rockey, William M et al. (2016) In vitro RNA SELEX for the generation of chemically-optimized therapeutic RNA drugs. Methods 103:167-74|
|Dickey, David D; Giangrande, Paloma H (2016) Oligonucleotide aptamers: A next-generation technology for the capture and detection of circulating tumor cells. Methods 97:94-103|
|Iaboni, Margherita; Russo, Valentina; Fontanella, Raffaela et al. (2016) Aptamer-miRNA-212 Conjugate Sensitizes NSCLC Cells to TRAIL. Mol Ther Nucleic Acids 5:e289|
|Xu, Xiaojun; Dickey, David D; Chen, Shi-Jie et al. (2016) Structural computational modeling of RNA aptamers. Methods 103:175-9|
|Thiel, William H; Giangrande, Paloma H (2016) Analyzing HT-SELEX data with the Galaxy Project tools--A web based bioinformatics platform for biomedical research. Methods 97:3-10|
|Littlejohn, Nicole K; Keen, Henry L; Weidemann, Benjamin J et al. (2016) Suppression of Resting Metabolism by the Angiotensin AT2 Receptor. Cell Rep 16:1548-1560|
|Thiel, William H; Giangrande, Paloma H (2016) AFBI assay - Aptamer Fluorescence Binding and Internalization assay for cultured adherent cells. Methods 103:180-7|
|Thiel, William H; Esposito, Carla L; Dickey, David D et al. (2016) Smooth Muscle Cell-targeted RNA Aptamer Inhibits Neointimal Formation. Mol Ther 24:779-87|
Showing the most recent 10 out of 21 publications